Marin S, Querol R, Campins L, Miarons M, Font A, Lianes P
Pharmacy, Consorci Sanitari del Maresme, Mataro, Catalunya, Spain.
Oncology, Consorci Sanitari del Maresme, Mataro, Catalunya, Spain.
J Clin Pharm Ther. 2018 Oct;43(5):714-716. doi: 10.1111/jcpt.12693. Epub 2018 May 2.
Abiraterone acetate (AA) is an androgen receptor axis inhibitor, indicated together with prednisone, for metastatic castration-resistant prostate cancer. Withdrawal syndrome for classical antiandrogen treatments is well known, but not so known for AA. Abiraterone withdrawal syndrome (AWS) could be related to simultaneous prednisone discontinuation or to an androgenic effect of AA metabolites.
A case is described of a patient with long-term AWS without prednisone discontinuation. The clinical and prostate-specific antigen (PSA) response allowed an 8-month delay in docetaxel treatment.
Prednisone did not play a role in AWS in this case. The long-term response allowed a delay in future treatment.
醋酸阿比特龙（AA）是一种雄激素受体轴抑制剂，与泼尼松联合用于治疗转移性去势抵抗性前列腺癌。经典抗雄激素治疗的撤药综合征广为人知，但AA的撤药综合征却鲜为人知。阿比特龙撤药综合征（AWS）可能与同时停用泼尼松或AA代谢产物的雄激素作用有关。
本文描述了一例未停用泼尼松却出现长期AWS的患者。临床和前列腺特异性抗原（PSA）反应使多西他赛治疗延迟了8个月。
在该病例中，泼尼松在AWS中未起作用。长期反应使未来治疗得以延迟。
